ArticleNews reportPHN-05282026-11-01 21:00 CT

Hanmi’s eppe 1st-month costs 26-44% less than imported obesity drugs on Doctornow

Source · Korea Biomedical Review

TLDR

Korea Biomedical Review reported that Hanmi Pharmaceutical’s newly launched eppe (efpeglenatide) had first-month prices 26–30% below Wegovy and 41–44% below Mounjaro in Doctornow listings. Prices at clinics in Seoul and Gyeonggi Province ranged from 160,000 to 200,000 won, but the article cautioned that these comparisons do not establish longer-term treatment costs.

01—Key points

01The report identifies eppe as Korea’s first domestically developed GLP-1 obesity treatment, launched after Korean approval on Oct. 7.
02Prices vary by medical institution, and different treatment schedules limit comparisons of longer-term costs.
03All three drugs are currently paid for out of pocket when prescribed for obesity in Korea.

Why it matters Editorial

The reported price differences highlight first-month out-of-pocket costs in Korea’s obesity-drug market without establishing longer-term affordability.

Read the original at Korea Biomedical Review↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.